دورية أكاديمية

Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 + T-myeloid cell networks in melanoma.

التفاصيل البيبلوغرافية
العنوان: Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 + T-myeloid cell networks in melanoma.
المؤلفون: Barras D; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland., Ghisoni E; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.; Service of Immuno-oncology, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Chiffelle J; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland., Orcurto A; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.; Service of Immuno-oncology, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Dagher J; Unit of Translational Oncopathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland., Fahr N; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland., Benedetti F; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland., Crespo I; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland., Grimm AJ; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland., Morotti M; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland., Zimmermann S; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.; Service of Immuno-oncology, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Duran R; Department of Radiology and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland., Imbimbo M; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.; Service of Immuno-oncology, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., de Olza MO; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.; Service of Immuno-oncology, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Navarro B; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.; Service of Immuno-oncology, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Homicsko K; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.; Service of Immuno-oncology, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Bobisse S; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland., Labes D; Flow Cytometry Facility, Department of Formation and Research, University of Lausanne, Epalinges, Switzerland., Tsourti Z; Scientific Research Consulting Hellas, Athens, Greece., Andriakopoulou C; Scientific Research Consulting Hellas, Athens, Greece., Herrera F; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Service of Radiation Oncology, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Pétremand R; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland., Dummer R; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Berthod G; Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Kraemer AI; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland., Huber F; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland., Thevenet J; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.; Department of Oncology, Center of Experimental Therapeutics, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland., Bassani-Sternberg M; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland., Schaefer N; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland., Prior JO; Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Lausanne, Switzerland., Matter M; Department of Visceral Surgery, Lausanne University Hospital, and University of Lausanne, Lausannne, Switzerland., Aedo V; Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Dromain C; Department of Radiology and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland., Corria-Osorio J; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland., Tissot S; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.; Department of Oncology, Center of Experimental Therapeutics, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland., Kandalaft LE; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.; Department of Oncology, Center of Experimental Therapeutics, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland., Gottardo R; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Biomedical Data Science Center and Swiss Institute of Bioinformatics, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland., Pittet M; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland., Sempoux C; Unit of Translational Oncopathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland., Michielin O; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Dafni U; Faculty of Nursing, National and Kapodistrian University of Athens, Athens, Greece., Trueb L; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.; Service of Immuno-oncology, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland., Harari A; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland., Laniti DD; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland., Coukos G; Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Agora Cancer Research Center, Lausanne, Switzerland.; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.; Service of Immuno-oncology, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
المصدر: Science immunology [Sci Immunol] 2024 Feb 02; Vol. 9 (92), pp. eadg7995. Date of Electronic Publication: 2024 Feb 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101688624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2470-9468 (Electronic) Linking ISSN: 24709468 NLM ISO Abbreviation: Sci Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : American Association for the Advancement of Science, [2016]-
مواضيع طبية MeSH: Immunotherapy, Adoptive* , Melanoma*/genetics, Humans ; Lymphocytes, Tumor-Infiltrating/metabolism ; Proteomics ; CD8-Positive T-Lymphocytes/metabolism ; Tumor Microenvironment
مستخلص: Adoptive cell therapy (ACT) using ex vivo-expanded tumor-infiltrating lymphocytes (TILs) can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a fraction of patients. Using longitudinal samples from 13 patients with metastatic melanoma treated with TIL-ACT in a phase 1 clinical study, we interrogated cellular states within the tumor microenvironment (TME) and their interactions. We performed bulk and single-cell RNA sequencing, whole-exome sequencing, and spatial proteomic analyses in pre- and post-ACT tumor tissues, finding that ACT responders exhibited higher basal tumor cell-intrinsic immunogenicity and mutational burden. Compared with nonresponders, CD8 + TILs exhibited increased cytotoxicity, exhaustion, and costimulation, whereas myeloid cells had increased type I interferon signaling in responders. Cell-cell interaction prediction analyses corroborated by spatial neighborhood analyses revealed that responders had rich baseline intratumoral and stromal tumor-reactive T cell networks with activated myeloid populations. Successful TIL-ACT therapy further reprogrammed the myeloid compartment and increased TIL-myeloid networks. Our systematic target discovery study identifies potential T-myeloid cell network-based biomarkers that could improve patient selection and guide the design of ACT clinical trials.
تواريخ الأحداث: Date Created: 20240202 Date Completed: 20240205 Latest Revision: 20240214
رمز التحديث: 20240215
DOI: 10.1126/sciimmunol.adg7995
PMID: 38306416
قاعدة البيانات: MEDLINE
الوصف
تدمد:2470-9468
DOI:10.1126/sciimmunol.adg7995